false
0000740260
0000740260
2024-03-04
2024-03-04
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
March 4, 2024
Ventas, Inc.
(Exact Name of Registrant as Specified in
Its Charter)
Delaware |
|
1-10989 |
|
61-1055020 |
(State or Other Jurisdiction of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
353
N. Clark Street, Suite
3300, Chicago, Illinois |
|
60654 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including
Area Code: (877) 483-6827
Not applicable
Former Name or Former Address, if Changed
Since Last Report
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which
registered |
Common stock, $0.25 par value |
|
VTR |
|
New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 4, 2024, James D. (“Denny”) Shelton
advised the Board of Directors (the “Board”) of Ventas, Inc. (we,” “us,” “our,”
“Company” and other similar terms) that he will not stand for re-election as a director of the Company at the 2024
annual meeting of stockholders (the “2024 Annual Meeting”). Mr. Shelton currently serves as the Company’s
Lead Independent Director and is a member of the Compensation Committee and the Nominating, Governance and Corporate Responsibility
Committee of the Board. Mr. Shelton’s decision to pursue retirement follows 16 years of service on the Board and various
Board committees and is not the result of any disagreement with the Company on any matter related to the Company’s operations,
policies, or practices. The Board and the Company are grateful for Mr. Shelton’s service and wish him well
following his retirement from the Board. The Board has unanimously appointed Roxanne Martino, a director since 2016 and former CEO
of Aurora Investment Management, as Lead Independent Director, effective following the 2024 Annual Meeting.
Item 8.01 Other Events.
On March 4, 2024, the Company issued a
press release announcing Mr. Shelton’s retirement from the Board and Ms. Martino’s appointment as Lead
Independent Director. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and
incorporated herein by reference.
Item
9.01. Financial Statements and Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
VENTAS, INC. |
|
|
Date: March 4, 2024 |
By: |
/s/ Carey S. Roberts |
|
|
Carey S. Roberts |
|
|
Executive Vice President, General Counsel and Ethics and Compliance Officer |
Exhibit 99.1
Ventas Announces James D. Shelton Has Decided
to Retire from Board
Before 2024 Annual Meeting
Roxanne M. Martino Appointed to Serve as Lead
Independent Director Following 2024 Annual Meeting
CHICAGO – MARCH 4, 2024 – Ventas, Inc. (NYSE:
VTR) today announced that James D. (“Denny”) Shelton , the Lead Independent Director of the Ventas Board of Directors, has decided
to retire from the Board, effective immediately prior to the 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”).
The independent directors have unanimously appointed Roxanne Martino, a Ventas director since 2016 and former CEO of Aurora Investment
Management, as Lead Independent Director, effective following the 2024 Annual Meeting.
Debra A. Cafaro, Ventas Chairman and CEO, said, “On behalf of
Ventas, I thank Denny for his outstanding contributions during his 16 years on the Board and eight years as Lead Independent Director.
Denny’s excellent judgment, extensive experience and deep healthcare knowledge proved invaluable to the Company, and his commitment
to strong governance and board refreshment have helped create an independent Board that is diverse, distinguished by the professional
achievement of its members and focused on shareholders. His decision to retire from the Board is well-earned after years of service, and
we will miss him.”
“I am pleased to take on the role of Lead Independent Director
and will continue to provide my perspectives to the Board, informed by my leadership experience, healthcare knowledge and investment expertise,”
said Ms. Martino. “Since joining the Board in 2016 shortly after meeting Debbie, I have been deeply engaged in the important
work of enhancing value for Ventas shareholders, and I look forward to continuing to contribute to the Company’s growth and success.”
“It has been a privilege to serve as a member of the Ventas Board
and as Lead Independent Director, lending my perspective as the Company has built a leading portfolio of senior housing and healthcare
real estate and delivered significant value to shareholders,” said Mr. Shelton. “I thank the Ventas Board for their partnership
and congratulate Roxanne. Ventas is very well positioned for continued success as it advances its mission of enabling exceptional environments
for a large and growing aging population.”
Since joining the Ventas Board, Ms. Martino has brought extensive
expertise in investment strategy and capital allocation, finance and accounting and business leadership. Ms. Martino also brings
insights into the perspectives of institutional investors and healthcare leadership experience as Chairperson of the Ann & Robert
H. Lurie Children’s Hospital of Chicago Board of Directors. From 1990 to 2016, Ms. Martino led Aurora Investment Management,
a hedge fund investment firm, and its predecessor companies, including serving as Investment Committee Chair and CEO, building the firm
into one of the largest managers in the fund-of-funds industry with $14 billion in assets under management. She was inducted into the
Invest Hedge Hall of Fame in 2015.
In a separate release issued today, Ventas announced that Theodore
Bigman and Joe V. Rodriguez, Jr. have been appointed as independent members of the Company’s Board of Directors, effective
immediately.
About Ventas
Ventas, Inc. (NYSE: VTR) is a leading S&P 500 real estate
investment trust focused on delivering strong, sustainable shareholder returns by enabling exceptional environments that benefit a large
and growing aging population. The Company’s growth is fueled by its senior housing communities, which provide valuable services
to residents and enable them to thrive in supported environments. Ventas leverages its unmatched operational expertise, data-driven insights
from its Ventas Operational InsightsTM platform, extensive relationships and strong financial position to achieve its
goal of delivering outsized performance across approximately 1,400 properties. The Ventas portfolio is composed of senior housing communities,
outpatient medical buildings, research centers and healthcare facilities in North America and the United Kingdom. The Company benefits
from a seasoned team of talented professionals who share a commitment to excellence, integrity and a common purpose of helping people
live longer, healthier, happier lives.
Forward-Looking Statements
This communication includes forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
These forward-looking statements include, among others, statements of expectations, beliefs, future plans and strategies, anticipated
results from operations and developments and other matters that are not historical facts. Forward-looking statements include, among other
things, statements regarding our and our officers’ intent, belief or expectation as identified by the use of words such as “assume,”
“may,” “will,” “project,” “expect,” “believe,” “intend,” “anticipate,”
“seek,” “target,” “forecast,” “plan,” “potential,” “opportunity,”
“estimate,” “could,” “would,” “should” and other comparable and derivative terms or the
negatives thereof.
Forward-looking statements are based on management’s beliefs
as well as on a number of assumptions concerning future events. You should not put undue reliance on these forward-looking statements,
which are not a guarantee of performance and are subject to a number of uncertainties and other factors that could cause actual events
or results to differ materially from those expressed or implied by the forward-looking statements. We do not undertake a duty to update
these forward-looking statements, which speak only as of the date on which they are made. We urge you to carefully review the disclosures
we make concerning risks and uncertainties that may affect our business and future financial performance, including those made below and
in our filings with the Securities and Exchange Commission, such as in the sections titled “Cautionary Statements - Summary Risk
Factors,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of
Operations” in our Annual Report on Form 10-K for the year ended December 31, 2023.
Certain factors that could affect our future results and our ability
to achieve our stated goals include, but are not limited to: (a) our ability to achieve the anticipated benefits and synergies from,
and effectively integrate, our completed or anticipated acquisitions and investments of properties, including our ownership of the properties
included in our equitized loan portfolio; (b) our exposure and the exposure of our tenants, managers and borrowers to complex healthcare
and other regulation, including evolving laws and regulations regarding data privacy and cybersecurity and environmental matters, and
the challenges and expense associated with complying with such regulation; (c) the potential for significant general and commercial
claims, legal actions, regulatory proceedings or enforcement actions that could subject us or our tenants, managers or borrowers to increased
operating costs, uninsured liabilities, fines or significant operational limitations, including the loss or suspension of or moratoriums
on accreditations, licenses or certificates of need, suspension of or nonpayment for new admissions, denial of reimbursement, suspension,
decertification or exclusion from federal, state or foreign healthcare programs or the closure of facilities or communities; (d) the
impact of market and general economic conditions on us, our tenants, managers and borrowers and in areas in which our properties are geographically
concentrated, including macroeconomic trends and financial market events, such as bank failures and other events affecting financial institutions,
market volatility, increases in inflation, changes in or elevated interest and exchange rates, tightening of lending standards and reduced
availability of credit or capital, geopolitical conditions, supply chain pressures, rising labor costs and historically low unemployment,
events that affect consumer confidence, our occupancy rates and resident fee revenues, and the actual and perceived state of the real
estate markets, labor markets and public and private capital markets; (e) our reliance and the reliance of our tenants, managers
and borrowers on the financial, credit and capital markets and the risk that those markets may be disrupted or become constrained, including
as a result of bank failures or concerns or rumors about such events, tightening of lending standards and reduced availability of credit
or capital; (f) the secondary and tertiary effects of the COVID-19 pandemic on our business, financial condition and results of operations
and the implementation and impact of regulations related to the CARES Act and other stimulus legislation, including the risk that some
or all of the CARES Act or other COVID-19 relief payments we or our tenants, managers or borrowers received could be recouped; (g) our
ability, and the ability of our tenants, managers and borrowers, to navigate the trends impacting our or their businesses and the industries
in which we or they operate, and the financial condition or business prospect of our tenants, managers and borrowers; (h) the risk
of bankruptcy, inability to obtain benefits from governmental programs, insolvency or financial deterioration of our tenants, managers,
borrowers and other obligors which may, among other things, have an adverse impact on the ability of such parties to make payments or
meet their other obligations to us, which could have an adverse impact on our results of operations and financial condition; (i) the
risk that the borrowers under our loans or other investments default or that, to the extent we are able to foreclose or otherwise acquire
the collateral securing our loans or other investments, we will be required to incur additional expense or indebtedness in connection
therewith, that the assets will underperform expectations or that we may not be able to subsequently dispose of all or part of such assets
on favorable terms; (j) our current and future amount of outstanding indebtedness, and our ability to access capital and to incur
additional debt which is subject to our compliance with covenants in instruments governing our and our subsidiaries’ existing indebtedness;
(k) the recognition of reserves, allowances, credit losses or impairment charges are inherently uncertain, may increase or decrease
in the future and may not represent or reflect the ultimate value of, or loss that we ultimately realize with respect to, the relevant
assets, which could have an adverse impact on our results of operations and financial condition; (l) the non-renewal of any leases
or management agreement or defaults by tenants or managers thereunder and the risk of our inability to replace those tenants or managers
on a timely basis or on favorable terms, if at all; (m) our ability to identify and consummate future investments in or dispositions
of healthcare assets and effectively manage our portfolio opportunities and our investments in co-investment vehicles, joint ventures
and minority interests, including our ability to dispose of such assets on favorable terms as a result of rights of first offer or rights
of first refusal in favor of third parties; (n) risks related to development, redevelopment and construction projects, including
costs associated with inflation, rising or elevated interest rates, labor conditions and supply chain pressures, and risks related to
increased construction and development in markets in which our properties are located, including adverse effect on our future occupancy
rates; (o) our ability to attract and retain talented employees; (p) the limitations and significant requirements imposed upon
our business as a result of our status as a REIT and the adverse consequences (including the possible loss of our status as a REIT) that
would result if we are not able to comply with such requirements; (q) the ownership limits contained in our certificate of incorporation
with respect to our capital stock in order to preserve our qualification as a REIT, which may delay, defer or prevent a change of control
of our company; (r) the risk of changes in healthcare law or regulation or in tax laws, guidance and interpretations, particularly
as applied to REITs, that could adversely affect us or our tenants, managers or borrowers; (s) increases in our borrowing costs as
a result of becoming more leveraged, including in connection with acquisitions or other investment activity and rising or elevated interest
rates; (t) our reliance on third-party managers and tenants to operate or exert substantial control over properties they manage for
or rent from us, which limits our control and influence over such operations and results; (u) our exposure to various operational
risks, liabilities and claims from our operating assets; (v) our dependency on a limited number of tenants and managers for a significant
portion of our revenues and operating income; (w) our exposure to particular risks due to our specific asset classes and operating
markets, such as adverse changes affecting our specific asset classes and the real estate industry, the competitiveness or financial viability
of hospitals on or near the campuses where our outpatient medical buildings are located, our relationships with universities, the level
of expense and uncertainty of our research tenants, and the limitation of our uses of some properties we own that are subject to ground
lease, air rights or other restrictive agreements; (x) the risk of damage to our reputation; (y) the availability, adequacy
and pricing of insurance coverage provided by our policies and policies maintained by our tenants, managers or other counterparties; (z) the
risk of exposure to unknown liabilities from our investments in properties or businesses; (aa) the occurrence of cybersecurity threats
and incidents that could disrupt our or our tenants’, managers’ or borrower’s operations, result in the loss of confidential
or personal information or damage our business relationships and reputation; (bb) the failure to maintain effective internal controls,
which could harm our business, results of operations and financial condition; (cc) the impact of merger, acquisition and investment activity
in the healthcare industry or otherwise affecting our tenants, managers or borrowers; (dd) disruptions to the management and operations
of our business and the uncertainties caused by activist investors; (ee) the risk of catastrophic or extreme weather and other natural
events and the physical effects of climate change; (ff) the risk of potential dilution resulting from future sales or issuances of our
equity securities; and (gg) the other factors set forth in our periodic filings with the Securities and Exchange Commission.
Contacts
Investors
BJ Grant
(877) 4-VENTAS
Media
Andrew Siegel / Joseph Sala / Greg Klassen
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449
v3.24.0.1
Cover
|
Mar. 04, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Mar. 04, 2024
|
Entity File Number |
1-10989
|
Entity Registrant Name |
Ventas, Inc.
|
Entity Central Index Key |
0000740260
|
Entity Tax Identification Number |
61-1055020
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
353
N. Clark Street
|
Entity Address, Address Line Two |
Suite
3300
|
Entity Address, City or Town |
Chicago
|
Entity Address, State or Province |
IL
|
Entity Address, Postal Zip Code |
60654
|
City Area Code |
877
|
Local Phone Number |
483-6827
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common stock, $0.25 par value
|
Trading Symbol |
VTR
|
Security Exchange Name |
NYSE
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Grafico Azioni Ventas (NYSE:VTR)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Ventas (NYSE:VTR)
Storico
Da Apr 2023 a Apr 2024